Risk stratification of organ-specific GVHD can be improved by single-nucleotide polymorphism-based risk models

Bone Marrow Transplantation

Volumn 49, Issue 5, 2014, Pages 649-656

  Kim, D ^a   Won, H H ^b   Su, S ^c   Cheng, L ^c   Xu, W ^c   Hamad, N ^a   Uhm, J ^a   Gupta, V ^a   Kuruvilla, J ^a   Messner, H A ^a   Lipton, J H ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b Samsung Medical Center   (South Korea)

^c PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

GVHD; risk model; Single nucleotide polymorphism

Indexed keywords

CYTOKINE; FAS ANTIGEN; FC RECEPTOR IIA; PLATELET DERIVED GROWTH FACTOR; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; FAS PROTEIN, HUMAN; FC RECEPTOR; FCGR2A PROTEIN, HUMAN; GENETIC MARKER; TGFB1 PROTEIN, HUMAN;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; AGED; APOPTOSIS; ARTICLE; CHRONIC GRAFT VERSUS HOST DISEASE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MODEL; MOUTH DISEASE; PRIORITY JOURNAL; RISK ASSESSMENT; SCORING SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM; ACUTE DISEASE; BIOLOGICAL MODEL; CHRONIC DISEASE; EPIDEMIOLOGY; GENETIC MARKER; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; GRAFT VS HOST DISEASE; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; RISK FACTOR; YOUNG ADULT;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; ANTIGENS, CD95; CHRONIC DISEASE; FEMALE; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GRAFT VS HOST DISEASE; HUMANS; MALE; MIDDLE AGED; MODELS, GENETIC; MULTIVARIATE ANALYSIS; PLATELET-DERIVED GROWTH FACTOR; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, IGG; RISK FACTORS; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; YOUNG ADULT;

EID: 84900302800     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2014.20     Document Type: Article

References (42)

1. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 945-956
2. Anderson BE, Taylor PA, McNiff JM, Jain D, Demetris AJ, Panoskaltsis-Mortari A et al. Effects of donor T-cell trafficking and priming site on graft-versus-host disease induction by naive and memory phenotype CD4 T cells. Blood 2008; 111: 5242-5251
3. Biedermann BC, Sahner S, Gregor M, Tsakiris DA, Jeanneret C, Pober JS et al. Endothelial injury mediated by cytotoxic T lymphocytes and loss of microvessels in chronic graft versus host disease. Lancet 2002; 359: 2078-2083
4. Shimabukuro-Vornhagen A, Hallek MJ, Storb RF, Von Bergwelt-Baildon MS. The role of B cells in the pathogenesis of graft-versus-host disease. Blood 2009; 114: 4919-4927
5. Kim D, Yun J, Won H-H, Cheng L, Su J, Xu W et al. Multiple single nucleotide polymorphism (SNP)-based risk model for clinical outcomes following allogeneic stem cell transplantation, especially for acute graft-versus-host disease. Transplantation 2012; 94: 1250-1257
6. Cavet J, Dickinson AM, Norden J, Taylor PR, Jackson GH, Middleton PG. Interferongamma and interleukin-6 gene polymorphisms associate with graft-versus-host disease in HLA-matched sibling bone marrow transplantation. Blood 2001; 98: 1594-1600
7. Keen LJ, DeFor TE, Bidwell JL, Davies SM, Bradley BA, Hows JM. Interleukin-10 and tumor necrosis factor alpha region haplotypes predict transplant-related mortality after unrelated donor stem cell transplantation. Blood 2004; 103: 3599-3602
8. Kim DH, Lee NY, Sohn SK, Baek JH, Kim JG, Suh JS et al. IL-10 promoter gene polymorphism associated with the occurrence of chronic GVHD and its clinical course during systemic immunosuppressive treatment for chronic GVHD after allogeneic peripheral blood stem cell transplantation. Transplantation 2005; 79: 1615-1622
9. Stark GL, Dickinson AM, Jackson GH, Taylor PR, Proctor SJ, Middleton PG. Tumour necrosis factor receptor type II 196M/R genotype correlates with circulating soluble receptor levels in normal subjects and with graft-versus-host disease after sibling allogeneic bone marrow transplantation. Transplantation 2003; 76: 1742-1749
10. Sanchez-Valdepenas C, Casanova L, Colmenero I, Arriero M, Gonzalez A, Lozano N et al. Nuclear factor-kappaB inducing kinase is required for graft-versus-host disease. Haematologica 2010; 95: 2111-2118
11. O'Shaughnessy MJ, Vogtenhuber C, Sun K, Sitcheran R, Baldwin AS, Murphy WJ et al. Ex vivo inhibition of NF-kappaB signaling in alloreactive T-cells prevents graft-versus-host disease. Am J Transplant 2009; 9: 452-462
12. Maciejewski JP, Selleri C, Sato T, Anderson S, Young NS. Increased expression of Fas antigen on bone marrow CD34 cells of patients with aplastic anaemia. Br J Haematol 1995; 91: 245-252
13. Hongo D, Bryson JS, Kaplan AM, Cohen DA. Endogenous nitric oxide protects against T cell-dependent lethality during graft-versus-host disease and idiopathic pneumonia syndrome. J Immunol 2004; 173: 1744-1756
14. Tichelli A, Gratwohl A. Vascular endothelium as 'novel' target of graft-versus-host disease. Best Pract Res Clin Haematol 2008; 21: 139-148
15. Hoffman RA, Nussler NC, Gleixner SL, Zhang G, Ford HR, Langrehr JM et al. Attenuation of lethal graft-versus-host disease by inhibition of nitric oxide synthase. Transplantation 1997; 63: 94-100
16. Svegliati S, Olivieri A, Campelli N, Luchetti M, Poloni A, Trappolini S et al. Stimulatory autoantibodies to PDGF receptor in patients with extensive chronic graft-versus-host disease. Blood 2007; 110: 237-241
17. Leffell MS, Vogelsang GB, Lucas DP, Delaney NL, Zachary AA. Association between TGF-beta expression and severe GVHD in allogeneic bone marrow transplantation. Transplant Proc 2001; 33: 485-486
18. Hattori H, Matsuzaki A, Suminoe A, Ihara K, Nagatoshi Y, Sakata N et al. Polymorphisms of transforming growth factor-beta1 and transforming growth factorbeta1 type II receptor genes are associated with acute graft-versus-host disease in children with HLA-matched sibling bone marrow transplantation. Bone Marrow Transplant 2002; 30: 665-671
19. Elmaagacli AH, Koldehoff M, Hindahl H, Steckel NK, Trenschel R, Peceny R et al. Mutations in innate immune system NOD2/CARD 15 and TLR-4 (Thr399Ile) genes influence the risk for severe acute graft-versus-host disease in patients who underwent an allogeneic transplantation. Transplantation 2006; 81: 247-254
20. Holler E, Rogler G, Herfarth H, Brenmoehl J, Wild PJ, Hahn J et al. Both donor and recipient NOD2/CARD15 mutations associate with transplant-related mortality and GvHD following allogeneic stem cell transplantation. Blood 2004; 104: 889-894
21. Mayor NP, Shaw BE, Hughes DA, Maldonado-Torres H, Madrigal JA, Keshav S et al. Single nucleotide polymorphisms in the NOD2/CARD15 gene are associated with an increased risk of relapse and death for patients with acute leukemia after hematopoietic stem-cell transplantation with unrelated donors. J Clin Oncol 2007; 25: 4262-4269
22. Holler E, Rogler G, Brenmoehl J, Hahn J, Herfarth H, Greinix H et al. Prognostic significance of NOD2/CARD15 variants in HLA-identical sibling hematopoietic stem cell transplantation: Effect on long-term outcome is confirmed in 2 independent cohorts and may be modulated by the type of gastrointestinal decontamination. Blood 2006; 107: 4189-4193
23. Rocha V, Franco RF, Porcher R, Bittencourt H, Silva Jr WA, Latouche A et al. Host defense and inflammatory gene polymorphisms are associated with outcomes after HLA-identical sibling bone marrow transplantation. Blood 2002; 100: 3908-3918
24. Kim DH, Sriharsha L, Xu W, Kamel-Reid S, Liu X, Siminovitch K et al. Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia. Clin Cancer Res 2009; 15: 4750-4758
25. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995; 15: 825-828
26. Lee SJ, Vogelsang G, Flowers ME. Chronic graft-versus-host disease. Biol Blood Marrow Transplant 2003; 9: 215-233
27. Zhang MJ, Zhang X, Scheike TH. Modeling cumulative incidence function for competing risks data. Expert Rev Clin Pharmacol 2008; 1: 391-400
28. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: Analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21: 263-265
29. Welniak LA, Blazar BR, Murphy WJ. Immunobiology of allogeneic hematopoietic stem cell transplantation. Annu Rev Immunol 2007; 25: 139-170
30. Ferrara JL, Reddy P. Pathophysiology of graft-versus-host disease. Semin Hematol 2006; 43: 3-10
31. Dickinson AM, Holler E. Polymorphisms of cytokine and innate immunity genes and GVHD. Best Pract Res Clin Haematol 2008; 21: 149-164
32. Cullup H, Dickinson AM, Jackson GH, Taylor PR, Cavet J, Middleton PG. Donor interleukin 1 receptor antagonist genotype associated with acute graft-versushost disease in human leucocyte antigen-matched sibling allogeneic transplants. Br J Haematol 2001; 113: 807-813
33. Dickinson AM, Charron D. Non-HLA immunogenetics in hematopoietic stem cell transplantation. Curr Opin Immunol 2005; 17: 517-525
34. Fiorentino DF, Zlotnik A, Vieira P, Mosmann TR, Howard M, Moore KW et al. IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J Immunol 1991; 146: 3444-3451
35. Magro L, Catteau B, Coiteux V, Bruno B, Jouet JP, Yakoub-Agha I. Efficacy of imatinib mesylate in the treatment of refractory sclerodermatous chronic GVHD. Bone Marrow Transplant 2008; 42: 757-760
36. Niculescu F, Niculescu T, Nguyen P, Puliaev R, Papadimitriou JC, Gaspari A et al. Both apoptosis and complement membrane attack complex deposition are major features of murine acute graft-vs-host disease. Exp Mol Pathol 2005; 79: 136-145
37. Murphy GF, Korngold R. Significance of selectively targeted apoptotic rete cells in graft-versus-host disease. Biol Blood Marrow Transplant 2004; 10: 357-365
38. Gilliam AC, Whitaker-Menezes D, Korngold R, Murphy GF. Apoptosis is the predominant form of epithelial target cell injury in acute experimental graft-versushost disease. J Invest Dermatol 1996; 107: 377-383
39. Van Den Brink MR, Moore E, Horndasch KJ, Crawford JM, Hoffman J, Murphy GF et al. Fas-deficient lpr mice are more susceptible to graft-versus-host disease. J Immunol 2000; 164: 469-480
40. Bashoura L, Gupta S, Jain A, Couriel DR, Komanduri KV, Eapen GA et al. Inhaled corticosteroids stabilize constrictive bronchiolitis after hematopoietic stem cell transplantation. Bone Marrow Transplant 2008; 41: 63-67
41. Kurt RA, Yalcindag N, Atilla H, Arat M. Topical cyclosporine-A in dry eye associated with chronic graft versus host disease. Ann Ophthalmol (Skokie) 2009; 41: 166-169
42. Lelli Jr GJ, Musch DC, Gupta A, Farjo QA, Nairus TM, Mian SI. Ophthalmic cyclosporine use in ocular GVHD. Cornea 2006; 25: 635-638.